Advances in treatment of hepatitis delta virus infection: Update on novel investigational drugs

doi:10.5501/wjv.v14.i2.102673

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 2

This Article

(93)

(74)

(0)

(2434)

(3)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Virol. Jun 25, 2025; 14(2): 102673
Published online Jun 25, 2025. doi: 10.5501/wjv.v14.i2.102673

Table 1 Current global society recommendations for hepatitis delta virus treatment

Society	Therapy	Length of therapy
AASLD	Peg-IFN α	12 months
APASL	Peg-IFN α	12-18 months
EASL	Peg-IFN α for 48 weeks (finite therapy)
	Or Bulevirtide 2 mg daily (long term therapy)
	Or Peg-IFN α + Bulevirtide

AASLD: American Association for the Study of Liver Disease; APASL: Asia-Pacific Association for Study of Liver; EASL: European Association for the Study of the Liver; Peg-IFN: Pegylated interferon.

Full Size Table

Citation: Park J, Sayed A, Nasir SA, Lim JK. Advances in treatment of hepatitis delta virus infection: Update on novel investigational drugs. World J Virol 2025; 14(2): 102673
URL: https://www.wjgnet.com/2220-3249/full/v14/i2/102673.htm
DOI: https://dx.doi.org/10.5501/wjv.v14.i2.102673

Park J, Sayed A, Nasir SA, Lim JK. Advances in treatment of hepatitis delta virus infection: Update on novel investigational drugs. World J Virol 2025; 14(2): 102673 [PMID: 40575639 DOI: 10.5501/wjv.v14.i2.102673]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.